Taiho Oncology at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Taiho Oncology exhibits at Booth 713 at ASH 2026 in New Orleans. Taiho Oncology supports symposia on treatment choices in acute myeloid leukemia, from frontline therapy to targeted agents. Its program features experts debating how to sequence treatments across the course of care, plus a second-opinion review of patient cases.
| Organization | ASH 2026 Attendance |
|---|---|
Taiho Oncology Princeton, NJ | |
US oncology arm of Japan's Taiho Pharmaceutical and Otsuka, developing and selling oral targeted cancer treatments. | Booth Exhibiting at Booth 713 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00am–10:00am Current Management Paradigms in Acute Myeloid Leukemia – A Second Opinion Case Review Difficult acute myeloid leukemia cases where doctors sought second opinions, paired with reviews of recent data, current management, and ongoing trials. Symposium Fri Dec 11 11:00am–2:00pm Medical Crossfire®: Precision Decisions in AML – Experts Debating Frontline Therapy, Targeted Agents, and Sequencing Across Care Frontline therapy, targeted drugs, and treatment sequencing in acute myeloid leukemia, framed around real questions from community oncologists. |
Instantly find 20 buyers from Taiho Oncology
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction